Metronidazole Dosing in Pregnancy
For bacterial vaginosis in pregnancy, use metronidazole 250 mg orally three times daily for 7 days starting in the second trimester; for trichomoniasis after the first trimester, use metronidazole 2 g orally as a single dose.
Critical First Trimester Contraindication
Metronidazole is contraindicated in the first trimester for trichomoniasis 1. The FDA label explicitly states this contraindication, and older CDC guidelines reinforced that metronidazole use for trichomoniasis should be "carefully evaluated" in the first trimester due to placental transfer and unknown effects on fetal organogenesis 2.
Bacterial Vaginosis Dosing
High-Risk Pregnant Women (Prior Preterm Delivery)
- Recommended regimen: Metronidazole 250 mg orally three times daily for 7 days 3
- Alternative regimens:
- Metronidazole 2 g orally single dose, OR
- Clindamycin 300 mg orally twice daily for 7 days
- Timing: Screen and treat at the earliest part of the second trimester 3
Low-Risk Pregnant Women (Symptomatic BV)
- Recommended regimen: Metronidazole 250 mg orally three times daily for 7 days 3
- Alternative regimens:
- Metronidazole 2 g orally single dose, OR
- Clindamycin 300 mg orally twice daily for 7 days, OR
- Metronidazole gel 0.75%, one applicator (5 g) intravaginally twice daily for 5 days
Rationale for lower doses: The 250 mg three times daily regimen (versus higher doses used in non-pregnant patients) is specifically recommended to minimize fetal exposure 3.
Trichomoniasis Dosing
After First Trimester
- Recommended regimen: Metronidazole 2 g orally as a single dose 3
- Alternative regimen: Metronidazole 500 mg orally twice daily for 7 days 3
- Timing: Only after completion of the first trimester 2
Important Clinical Caveats
Evidence Conflicts on Screening Benefits
The USPSTF recommends against routine screening for asymptomatic BV in low-risk pregnant women (Grade D recommendation) 4. Even for high-risk women, evidence is insufficient (I statement) 4, 5. This is because large trials showed that treating asymptomatic BV did not reduce preterm delivery rates 6, and treating asymptomatic trichomoniasis actually increased preterm delivery risk (19.0% vs 10.7%, p=0.004) 7.
However, symptomatic infections should still be treated to relieve symptoms and prevent complications 3, 5.
Safety Profile
- Metronidazole is FDA Pregnancy Category B 1
- No evidence of teratogenicity in human studies 8
- Crosses the placenta rapidly 1
- Pharmacokinetics remain stable throughout pregnancy 9
Avoid These Pitfalls
- Do not use clindamycin vaginal cream in pregnancy—two randomized trials showed increased preterm deliveries 3
- Do not use metronidazole gel for trichomoniasis—it doesn't achieve therapeutic levels in the urethra or perivaginal glands 3
- Do not treat asymptomatic trichomoniasis—evidence shows potential harm 7
Treatment Efficacy
Metronidazole achieves 90-95% cure rates for trichomoniasis and 77.8% resolution of BV when used appropriately 3, 6. Partner treatment is essential for trichomoniasis but not necessary for BV 3.